Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
0.978
-0.082 (-7.73%)
At close: Dec 20, 2024, 4:00 PM
0.990
+0.012 (1.21%)
After-hours: Dec 20, 2024, 5:15 PM EST

Company Description

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies.

It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma.

The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

Citius Oncology, Inc.
Citius Oncology logo
Country United States
Founded 2021
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
CEO Leonard Mazur

Contact Details

Address:
420 Lexington Avenue, Suite 2446
New York, New York 10170
United States
Phone 347-627-0058

Stock Details

Ticker Symbol CTOR
Exchange NASDAQ
Fiscal Year October - September
Reporting Currency USD
CIK Code 0001851484
ISIN Number US17331Y1091
SIC Code 2834

Key Executives

Name Position
Leonard L. Mazur Chairman, Chief Executive Officer and President
Jaime Bartushak Chief Financial Officer and Treasurer
Dr. Myron S. Czuczman M.D. Chief Medical Officer
Myron Z. Holubiak Secretary and Director

Latest SEC Filings

Date Type Title
Nov 12, 2024 8-K Current Report
Nov 6, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Sep 13, 2024 8-K Current Report
Sep 5, 2024 8-K Current Report
Sep 5, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 26, 2024 8-K/A [Amend] Current report
Aug 16, 2024 8-K Current Report
Aug 16, 2024 SC 13D General statement of acquisition of beneficial ownership
Aug 15, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Aug 13, 2024 25-NSE Filing